201 related articles for article (PubMed ID: 33034907)
1. Defining in vivo dose-response curves for kidney DNA adduct formation of aristolochic acid I in rat, mouse and human by an in vitro and physiologically based kinetic modeling approach.
Abdullah R; Wesseling S; Spenkelink B; Louisse J; Punt A; Rietjens IMCM
J Appl Toxicol; 2020 Dec; 40(12):1647-1660. PubMed ID: 33034907
[TBL] [Abstract][Full Text] [Related]
2. Predicting points of departure for risk assessment based on in vitro cytotoxicity data and physiologically based kinetic (PBK) modeling: The case of kidney toxicity induced by aristolochic acid I.
Abdullah R; Alhusainy W; Woutersen J; Rietjens IM; Punt A
Food Chem Toxicol; 2016 Jun; 92():104-16. PubMed ID: 27016491
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Aristolochic acid I derived DNA adduct levels in human renal toxicity models.
Bastek H; Zubel T; Stemmer K; Mangerich A; Beneke S; Dietrich DR
Toxicology; 2019 May; 420():29-38. PubMed ID: 30940547
[TBL] [Abstract][Full Text] [Related]
4. Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3-nitrobenzanthrone.
Arlt VM; Meinl W; Florian S; Nagy E; Barta F; Thomann M; Mrizova I; Krais AM; Liu M; Richards M; Mirza A; Kopka K; Phillips DH; Glatt H; Stiborova M; Schmeiser HH
Arch Toxicol; 2017 Apr; 91(4):1957-1975. PubMed ID: 27557898
[TBL] [Abstract][Full Text] [Related]
5. Co-Exposure to Aristolochic Acids I and II Increases DNA Adduct Formation Responsible for Aristolochic Acid I-Mediated Carcinogenicity in Rats.
Bárta F; Dedíková A; Bebová M; Dušková Š; Mráz J; Schmeiser HH; Arlt VM; Hodek P; Stiborová M
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638820
[TBL] [Abstract][Full Text] [Related]
6. The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers.
Stiborova M; Frei E; Arlt VM; Schmeiser HH
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):5-11. PubMed ID: 19365519
[TBL] [Abstract][Full Text] [Related]
7. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy.
Bieler CA; Stiborova M; Wiessler M; Cosyns JP; van Ypersele de Strihou C; Schmeiser HH
Carcinogenesis; 1997 May; 18(5):1063-7. PubMed ID: 9163697
[TBL] [Abstract][Full Text] [Related]
8. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review.
Arlt VM; Stiborova M; Schmeiser HH
Mutagenesis; 2002 Jul; 17(4):265-77. PubMed ID: 12110620
[TBL] [Abstract][Full Text] [Related]
9. The influence of dicoumarol on the bioactivation of the carcinogen aristolochic acid I in rats.
Stiborová M; Levová K; Bárta F; Šulc M; Frei E; Arlt VM; Schmeiser HH
Mutagenesis; 2014 May; 29(3):189-200. PubMed ID: 24598128
[TBL] [Abstract][Full Text] [Related]
10. The impact of p53 on aristolochic acid I-induced nephrotoxicity and DNA damage in vivo and in vitro.
Sborchia M; De Prez EG; Antoine MH; Bienfait L; Indra R; Valbuena G; Phillips DH; Nortier JL; Stiborová M; Keun HC; Arlt VM
Arch Toxicol; 2019 Nov; 93(11):3345-3366. PubMed ID: 31602497
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the mutagenicity of aristolochic acid I and aristolochic acid II in the gpt delta transgenic mouse kidney.
Xing G; Qi X; Chen M; Wu Y; Yao J; Gong L; Nohmi T; Luan Y; Ren J
Mutat Res; 2012 Mar; 743(1-2):52-8. PubMed ID: 22245565
[TBL] [Abstract][Full Text] [Related]
12. Comparison of DNA adduct formation by aristolochic acids in various in vitro activation systems by 32P-post-labelling: evidence for reductive activation by peroxidases.
Schmeiser HH; Frei E; Wiessler M; Stiborova M
Carcinogenesis; 1997 May; 18(5):1055-62. PubMed ID: 9163696
[TBL] [Abstract][Full Text] [Related]
13. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase.
Stiborová M; Frei E; Sopko B; Sopková K; Marková V; Lanková M; Kumstýrová T; Wiessler M; Schmeiser HH
Carcinogenesis; 2003 Oct; 24(10):1695-703. PubMed ID: 12869422
[TBL] [Abstract][Full Text] [Related]
14. Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: evidence of their contribution to aristolochic acid I detoxication and activation in rat liver.
Stiborova M; Mares J; Levova K; Pavlickova J; Barta F; Hodek P; Frei E; Schmeiser HH
Neuro Endocrinol Lett; 2011; 32 Suppl 1():121-30. PubMed ID: 22167220
[TBL] [Abstract][Full Text] [Related]
15. Characterization of DNA adducts formed by aristolochic acids in the target organ (forestomach) of rats by 32P-postlabelling analysis using different chromatographic procedures.
Stiborová M; Fernando RC; Schmeiser HH; Frei E; Pfau W; Wiessler M
Carcinogenesis; 1994 Jun; 15(6):1187-92. PubMed ID: 8020154
[TBL] [Abstract][Full Text] [Related]
16. Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy.
Stiborová M; Frei E; Breuer A; Bieler CA; Schmeiser HH
Exp Toxicol Pathol; 1999 Jul; 51(4-5):421-7. PubMed ID: 10445409
[TBL] [Abstract][Full Text] [Related]
17. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer.
Stiborová M; Frei E; Hodek P; Wiessler M; Schmeiser HH
Int J Cancer; 2005 Jan; 113(2):189-97. PubMed ID: 15386410
[TBL] [Abstract][Full Text] [Related]
18. Quantification of aristolochic acid-derived DNA adducts in rat kidney and liver by using liquid chromatography-electrospray ionization mass spectrometry.
Chan W; Yue H; Poon WT; Chan YW; Schmitz OJ; Kwong DW; Wong RN; Cai Z
Mutat Res; 2008 Nov; 646(1-2):17-24. PubMed ID: 18812181
[TBL] [Abstract][Full Text] [Related]
19. Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo.
Dračínská H; Bárta F; Levová K; Hudecová A; Moserová M; Schmeiser HH; Kopka K; Frei E; Arlt VM; Stiborová M
Toxicology; 2016 Feb; 344-346():7-18. PubMed ID: 26845733
[TBL] [Abstract][Full Text] [Related]
20. Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases.
Martinek V; Kubickova B; Arlt VM; Frei E; Schmeiser HH; Hudecek J; Stiborova M
Neuro Endocrinol Lett; 2011; 32 Suppl 1():57-70. PubMed ID: 22167209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
